New Orphan Drug Playing Field Requires Change in Tactics for Pharma Companies
Orphan drugs make up a growing slice of the pharmaceutical pipeline, with a significant share of new drug approvals, and payers are taking notice of their increasing market numbers and ultra-expensive price tags. Precision's Jeremy Schafer, PharmD, MBA, discusses how manufacturers may adjust their promotion of orphan drugs to ensure continued market access.
